Recent research shows that semaglutide (Ozempic®) can help patients with chronic kidney disease (CKD) and obesity, expanding its known benefits beyond diabetes treatment. The study, published in Nature Medicine, demonstrates substantial improvements in key kidney health markers. Study Details and Key Findings The international research, led by clinical pharmacologist Hiddo L. Heerspink from the University Medical Center Groningen, involved 101 participants across Canada, Germany, Spain, and the Netherlands. The 24-week trial divided participants into two groups, with half receiving semaglutide injections and half receiving a placebo. The results were striking: “The great thing is that the drug has both direct … Continue reading Ozempic-Linked Drug Semaglutide Trial Shows 52% Drop in Kidney Disease Markers – Is This the Next Big Breakthrough for CKD Patients?